Cervical Cancer Screening Guidelines
Screening Initiation
- Women should start screening at age 21 years, regardless of sexual activity history, as recommended by the Canadian guidelines 1, 2, 3
- Women under age 21 should not be screened, even if sexually active, due to the extremely low incidence of cervical cancer in this age group, with only 0.1% of all cases 2
Age-Specific Screening Intervals
- Women aged 21-29 years should screen every 3 years with Pap test alone, as recommended by the guidelines 1, 2, 3
- HPV testing should not be used in women aged 21-29 years for routine screening, as HPV infections are common and typically transient in younger women 1, 3
- Women aged 30-69 years can use either the preferred approach of screening every 5 years with HPV and Pap co-testing, or the acceptable alternative of screening every 3 years with Pap test alone 1, 2, 3
When to Stop Screening
- Women over age 65-70 years with adequate prior normal screening can discontinue screening, as defined by ≥3 consecutive negative Pap tests OR ≥2 consecutive negative HPV and Pap co-tests within the last 10 years, with the most recent test within the last 5 years 1, 3
- Continue screening beyond age 70 for women who have never been screened, have inadequate screening history, or have had recent abnormal results, as recommended by the Ca-A Cancer Journal for Clinicians guidelines 4, 5
Special Populations Requiring Modified Screening
- Women with HIV, immunosuppression, history of cervical cancer, or in utero DES exposure require more frequent screening, with HIV-positive and immunocompromised women being tested twice in the first year after diagnosis, then annually thereafter 1, 4, 5
- Women who have had a hysterectomy with cervix removal for benign reasons and have no history of high-grade precancerous lesions or cervical cancer can discontinue screening 1, 2
Evidence Supporting 3-Year Intervals
- Screening every 3 years versus annually improves cancer detection by less than 5%, making annual screening inefficient, and the 3-year interval substantially reduces false positives, unnecessary procedures, and healthcare costs while maintaining nearly equivalent cancer prevention 1, 2